Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV infection
An open phase I trial of 13% cellulose acetate phthalate vaginal microbicide with randomisation to an observation control
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children: a double-blind randomised placebo-controlled trial
Children with HIV in Africa – Pharmacokinetics and adherence/acceptability of simple antiretroviral regimens
Children with HIV in Africa – Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens.
A Phase I clinical trial to assess the safety and immunogenicity of three HIV GTU® MultiHIV DNA immunisations administered via the Intramuscular, Intradermal and Transcutaneous routes in healthy male and female volunteers.
A Phase I clinical trial to assess the safety and immunogenicity of HIV DNA-C CN54ENV immunisations administered via the Intramuscular and Intradermal methods with and without electroporation followed by boosting with recombinant HIV CN54gp140 in healthy male and female volunteers.
A randomized phase I/II study to assess the safety and immunogenicity of the DNA-GTU vaccine administered by two novel methods compared to placebo in HIV-infected patients on antiretroviral therapy
Development of AntiRetroviral Therapy in Africa - A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa
A Duel centre dose-Ranging trial of Emmelle (dextrin sulphate) gel in preparation for an African Microbicide trial
EuroVacc 03/ANRS vac20
A trial to compare the immune responses and safety of two versus three DNA HIV vaccine primes in combination regimens with a pox vector boost in healthy volunteers
A phase I trial to assess the safety of 4 ml DNA C (intramuscular [IM]), and the safety and immunogenicity of DNA C followed by NYVAC C (IM) in an open, randomised comparison to NYVAC C alone in healthy volunteers at low risk of human immunodeficiency virus (HIV) infection
An open, randomised trial to evaluate the activity and tolerability of combinations of reverse transcriptase and protease inhibitors, including induction therapy, in individuals with HIV-1 infection and CD4 counts greater than 25 x 106/L
Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients
A two-centre, randomised, double-blinded phase I study to evaluate the safety and immunogenicity of 2 doses of candidate HIV-1 Clade A DN/A vaccine or placebo followed by a candidate HIV-1 Clade A MVA vaccine or placebo in healthy volunteers at low risk of HIV infections
An open randomised trial to evaluate different therapeutic strategies of combination therapy for HIV-1 infection
A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children.
Optimising clinical care strategies and laboratory monitoring for cost-effective roll-out of antiretroviral therapy in Africa: the Lablite project
A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy.
A randomised, vaginal microbicide trial to assess the safety of dextrin sulphate gel versus vehicle placebo in Uganda
A randomised, placebo controlled, vaginal microbicide trial assessing the safety of PRO 2000/5 Gel (P) versus vehicle placebo in Uganda
A Phase I clinical trial to assess the safety and immunogenicity of three HIV CN54gp140 immunisations administered through the intramuscular, intranasal and intravaginal routes in healthy female volunteers
A randomised trial of dolutegravir-based antiretroviral therapy vs. standard of care in children with HIV infection starting first-line or switching to second-line antiretroviral therapy.
A phase II/III randomised, open-label study of combination antiretroviral regimens and treatment-switching strategies in HIV-1 infected antiretroviral naïve children >30 days and <18 years of age.
Plasma pharmacokinetic study of once versus twice daily abacavir as part of combination antiretroviral therapy in children with human immunodeficiency virus-1 infection aged 3 months to <36 months
PERA / PENTA 8
A randomised trial to evaluate the usefulness of resistance testing in the clinical management of children with HIV infection.
Protease Inhibitor monotherapy Versus Ongoing Triple-therapy in the long-term management of HIV infection
PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men
A phase II double-blind, placebo controlled, randomised, single centre study to assess the safety, tolerability and acceptability of dextrin-2-sulphate (DS) gel in sexually active female subjects and their male sexual partners at low risk of HIV infection
Strategy for Maintenance of HIV suppression with once daily integrase inhibitor +darunavir/ritonavir in children
A Phase I/II trial to assess safety and immunogenicity of intradermal (ID) DNA priming, intramuscular (IM) MVA and IM rgp140/GLA-AF boosting in healthy volunteers in Tanzania and to develop further HIV vaccine trial capacity building in Tanzania.
HIV vaccine trial capacity building in Tanzania and Mozambique by continued exploration of optimal DNA priming and MVA boosting strategies
A Phase I clinical trial investigating immunisation strategies using DNA, MVA and CN54rgp140 adjuvanted with GLA-AF to maximise antibody responses.